Bictegrav/Emtricit/Tenofov Ala
Brand name: Biktarvy
Rank #13 of 500 drugs by total cost
$1.29B
Total Cost
310,738
Total Claims
$1.29B
Total Cost
4,033
Prescribers
$4,154
Cost per Claim
33,335
Beneficiaries
324,252
30-Day Fills
$320K
Avg Cost/Provider
77
Avg Claims/Provider
About Bictegrav/Emtricit/Tenofov Ala
Bictegrav/Emtricit/Tenofov Ala (sold as Biktarvy) was prescribed 310,738 times by 4,033 Medicare Part D providers in 2023, costing the program $1.29B. At $4,154 per claim, this is a high-cost medication.
💰 This drug alone accounts for 0.5% of all Medicare Part D drug spending.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 10 | Dapagliflozin Propanediol (Farxiga) | $1.65B | 1,666,200 |
| 11 | Sitagliptin Phosphate (Januvia) | $1.54B | 1,567,668 |
| 12 | Sacubitril/Valsartan (Entresto) | $1.30B | 1,220,812 |
| 13 | Bictegrav/Emtricit/Tenofov Ala (Biktarvy) | $1.29B | 310,738 |
| 14 | Etanercept (Enbrel Sureclick) | $1.12B | 145,737 |
| 15 | Enzalutamide (Xtandi) | $985.0M | 72,710 |
| 16 | Mirabegron (Myrbetriq) | $927.5M | 1,407,073 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology